Customer-specific Preclinical Services Business
In addition to its core technology business, Heidelberg Pharma has the technical expertise and required infrastructure for in vivo pharmacology, cell biology, bioanalytics, molecular biology and chemistry and offers preclinical research services in the field of cancer as well as inflammatory and autoimmune diseases. In its research, the Company focuses on early substances (for example, lead structures to be optimized) up to the profiling of preclinical candidates. Both standard models and innovative developments are offered to customers for specified indications. Finally, Heidelberg Pharma develops customer-specific efficacy models upon request to support customers’ individual research activities.
Tumor Implantation Models
Heidelberg Pharma uses both syngeneic and human tumor implant models based on human tumor cells to conduct in-depth studies of potential oncology compounds. These models can be used to define parameters such as tumor growth, tumor regression or metastasis in comparison to reference agents. The visualization of metastases and orthotopic tumors via innovative imaging techniques is also part of the portfolio. Heidelberg Pharma complements the human tumors with syngeneic mouse and rat models. For preliminary testing, in vitro models are offered, for which Heidelberg Pharma has access to more than 100 types of tumor cell lines.
Inflammatory and Autoimmune Diseases
In the field of inflammatory and autoimmune diseases, Heidelberg Pharma offers a broad range of models and methods for examining the anti-inflammatory or immunomodulating effect and the mechanisms of new compounds. For this purpose, in addition to acute inflammation models, Heidelberg Pharma can draw on in vivo models for autoimmune diseases, such as for experimental autoimmune encephalomyelitis (EAE), multiple sclerosis (MS), collagen-induced arthritis (CIA) and Type 1 diabetes mellitus.
Bioanalytics analyses substance levels from in vivo experiments, particularly within the scope of pharmacokinetic studies. This process involves determining the substance level, e.g., in blood, serum or plasma, as well as a range of organs or tumors. Heidelberg Pharma also offers early ADME services. In vitro analyses test substances in terms of, for example, protein binding and metabolic stability. All studies can also be conducted with radiolabeled substances. In addition, Heidelberg Pharma offers the identification, synthesis and the in vitro and in vivo profiling of metabolites aimed at determining the substance's biological activity profile.